Saturday July 18th, 2009
Baxter are nothing if not prepared for this ‘swine flu’ outbreak if the wording in this 2008 US patent application is anything to go by:
“In particular preferred embodiments the composition or
vaccine comprises more than one antigen¦..such as
influenza A and influenza B in particular selected from of one
or more of the human H1N1, H2N2, H3N2, H5N1, H7N7, H1N2,
H9N2, H7N2, H7N3, H10N7 subtypes, of the pig flu H1N1,
H1N2, H3N1 and H3N2 subtypes, of the dog or horse flu H7N7,
H3N8 subtypes or of the avian H5N1, H7N2, H1N7, H7N3,
H13N6, H5N9, H11N6, H3N8, H9N2, H5N2, H4N8, H10N7, H2N2,
H8N4, H14N5, H6N5, H12N5 subtypes.
“Suitable adjuvants can be selected from mineral gels,
aluminium hydroxide, surface active substances, lysolecithin,
pluronic polyols, polyanions or oil emulsions such as water in
oil or oil in water, or a combination thereof. Of course the
selection of the adjuvant depends on the intended use.
E.g. toxicity may depend on the destined subject organism
and can vary from no toxicity to high toxicity.
“Three different influenza strains, two A-strains Hiroshima
(HR, H3N2), a New Calcdonia (NC, H1N1) and a B-strain,
Malaysia (MA), were produced in Vero cell cultures. After
virus propagation the infectious virus harvest is inactivated
prior to purification¦.